The Effectiveness of Trimetazidine Treatment in Patients with Stable Angina Pectoris of Various Duration: Results from the Choice 2 Study

Objectives: To evaluate the effect of adding trimetazidine to β-blockers and/or other antianginal drugs on the frequency of angina attacks and quality of life in patients with stable angina pectoris (AP) of various duration.
Methods and results: The data from the CHOICE 2 observational study, which was conducted in 46 cities in the Russian Federation by 185 GPs, was used. Trimetazidine MR (35 mg bid) was administered to 741 patients with a known duration of stable AP who still had angina attacks while taking β-blockers and/or other antianginal drugs. The patients were divided into 4 groups of stable AP duration: (i) 9 years. The patients were seen at baseline (W0) and after 2 weeks (W2) and 2, 4, and 6 months (M2, M4, and M6). Figure 1 shows the changes in mean weekly angina attacks and mean self-rated well-being (visual analog scale; 0-100) with trimetazidine. Conclusion: Trimetazidine rapidly and significantly decreased the frequency of angina attacks and increased patients’ quality of life in all groups, regardless of the duration of stable AP.